Please amend the claims as follows:

1. (Twice Amended) A chimaeric polypeptide comprising:

a binding portion comprising at least a portion of an immunoglobulin molecule [or an effective portion thereof] having specific binding affinity for a eucaryotic target cell surface component; [and]

an effector portion consisting of at least one copy [one or more copies] of an immunogenic peptide; and

a signal directing the immunogenic peptide to a particular cellular compartment, whereby binding of the chimaeric polypeptide to the cell surface component induces internalisation of at least the effector portion [so as] to allow the at least one copy of the immunogenic peptide to be presented by MHC molecules on the target cell surface.

6. (Amended) A polypeptide according to [any on of the preceding claims] claim 1 or 2, wherein after internalisation the peptide is presented on the surface of the target cell in association with class I MHC antigen so as to modulate a CTL response.

REMARKS

This Amendment and Response is submitted in response to the Office Action mailed January 3, 2000. Claims 1 to 3, 5 to 12 and 14 to 24 are pending. Claims 1 and 6 have been amended and Claim 13 has been canceled. Support for the amendments to Claims can be found generally throughout the specification and figures.

The Examiner has stated that the sequences on pages 10 and 11 must be followed by the appropriate sequence identification numbers to comply with the requirements of 37 C.F.R. 1.821 through 1.825. The specification has been amended to include the appropriate sequence identification numbers after each respective sequence.